Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AMD
Biotech
Astellas inks $6B Iveric buyout ahead of FDA eye disease ruling
Astellas agreed to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche.
Nick Paul Taylor
May 1, 2023 8:13am
Adverum lays off staff, funnels cash to single eye candidate
Jul 7, 2022 2:27pm
Stealth stumbles again as AMD joins list of clinical trial flops
May 2, 2022 9:05am
